Waystar Holding Corp. (WAY)
NEUTRALFundamental
60
Preço
$24.91
Capitalização de Mercado
$4.82B
Parte 1 · Quanto vale a empresa
Visão Geral
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and revenue capture, and analytics and reporting solutions. It primarily serves healthcare industry. The company was founded in 2017 and is headquartered in Lehi, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$1.21B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$135M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$283M
Capital Próprio Total
$3.88B
Passivo Total
$1.91B
Rácio de Liquidez
1.85
Cobertura de Juros
-
Dívida/EBITDA
3.80
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$20.84
Preço Atual
$24.91
Margem de Segurança
-19.5%
Intervalo de Valor Justo
$13.54 - $28.13
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
36.21
ROE
2.9%
Rácio P/B
1.22
P/FCF
19.74
Margem Bruta
-
ROIC
3.9%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
3.9%
WACC
8.4%
ROIC − WACC
-4.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (14)
- EPS shows upward trend
- P/FCF 19.74
- P/B Ratio 1.22
- Debt/Equity ratio
- Operating Margin 22.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 93% Buy
- Earnings Surprise avg 2.5%
- Earnings Quality (OCF/NI) 2.17
- Net Margin Trend 11.2% vs 8.5%
Reprovado (8)
- Price CAGR -17.46%
- ROIC 3.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.6%
- Share Dilution 24.9%
- Piotroski F-Score 4/9
Indisponível (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A emitir novas ações, diluindo a participação
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Matthew J. Hawkins | CEO & Director | 53 |
| Mr. Steven M. Oreskovich CPA | Advisor | 53 |
| Mr. T. Craig Bridge | Chief Transformation Officer | 52 |
| Ms. Alpana Wegner C.P.A. | Chief Financial Officer | 52 |
| Mr. Edward Akira Parker | Head of Investor Relations | - |
| Mr. Mark Encinger | Vice President of Treasury & Compliance | - |
| Mr. Gregory R. Packer | Chief Legal Officer & Secretary | 45 |
| Kristin Lee | Vice President of Communications | - |
| Mr. Brendan O'Connor | Senior Vice President of Corporate Development & Strategy | - |
| Ms. Kim Wittman | Chief People Officer | 46 |
Risco de Auditoria
1
Risco do Conselho
6
Risco de Remuneração
4
Risco dos Direitos dos Acionistas
8
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for WAY, sourced from Markets Gazette.
- 3/15/2026POSITIVEWaystar Stock Is Down 32% This Past Year, but One Fund Bought Up $11.5 Million Last Quarter
Despite a 32% stock decline over the past year, Waystar Holding Corp. has attracted significant investor interest, with one fund acquiring $11.5 million worth of shares in the last quarter. Waystar, a provider of cloud-based software for healthcare payment and revenue cycle management, appears to be viewed as undervalued by this particular investor. This substantial purchase, against a backdrop of recent poor stock performance, suggests a contrarian bet on the company's long-term prospects and its position within the healthcare technology sector.
via Markets Gazette